CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
December 11, 2019
Experimental Leukemia Combination Proves Toxic for Older, Frail PatientsPublished: December 11, 2019Category: News  About 32 percent of older, sicker patients enrolled on a leukemia clinical trial experienced serious side effects from a treatment that combined a chemotherapy and an immunotherapy drug, leading investigators to pause the trial and the U.S. Food and Drug Administration to eventually pull the combination from the current study. The study was presented by Dr. Annette Hay at the 61st American Society of Hematology (ASH) Annual Meeting the world’s largest conference devoted to blood diseases and blood cancers like lymphoma, the findings serve as both triumph and warning. Read More |
CCTG is celebrating 40 years of clinical trial excellencePublished: December 11, 2019Category: News  Next year is almost here and in 2020 CCTG will be marking our 40th anniversary! We would like to recognize this milestone and the hard work of our clinical trials network across Canada at an anniversary celebration during the 2020 CCTG Spring Meeting. Save the Date - evening of May 1, 2020
Event details to follow in the New Year - make sure to save the date and celebrate 40 years of clinical trial excellence. Read More |
 A Genetic, Risk-Stratified Randomized Phase II Study of Four Fludarabine/Antibody Combinations For Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia. This randomized phase II trial studies how well fludarabine (fludarabine phosphate) and rituximab with or without lenalidomide or cyclophosphamide work in treating patients with symptomatic chronic lymphocytic leukemia. Read More |
November 27, 2019
|
|
 We are coming up to a big holiday for American families. Please expect closure of U.S. Operations offices and laboratories on Thursday, November 28nd for the U.S. Thanksgiving. If you are planning to ship specimens to the U.S., please plan accordingly. Also remember that many of our U.S. collegues take additional holidays for an extra long weekend. Happy Thanksgiviing to our U.S friends! Read More |
An interview with Dr. Kuruvilla and Dr. Crump about CCTG LY17Published: November 27, 2019Category: News  CCTG LY17 is a A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma. The trial is looking to determine the overall response rate (complete and partial response) to novel combination therapy in patients with relapsed and refractory aggressive B cell lymphoma. Dr. Kuruvilla and Dr. Crump stress the importance of this trial, collaboration within CCTG, and the overall benefit of cancer clinical trials. (NCT02436707) Read More |
 CCTG is pleased to announce that the fall recipient of the Frances A. Shepherd Award is Dr. Assouline Division of Hematology McGill University, Jewish General Hospital Montreal, Quebec and the CCTG Hematologic Disease Site Chair Read More |
 IND229 Publication: A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2 - Positive Metastatic Breast Cancer IND222 Publication: A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: A CCTG study. Read More |
